ArticleOrphanet journal of rare diseases2021

Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.

Carolyn E Schwartz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.